ALISO VIEJO, Calif., Nov. 1, 2010 /PRNewswire-FirstCall/ -- AVANIR Pharmaceuticals, Inc. (Nasdaq: AVNR ) today announced a management conference call to discuss the approval of NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate) by the U.S. Food and Drug Administration (FDA). The call is scheduled for today, Monday November 1, 2010 at 5:15 a.m. Pacific time / 8:15 a.m. Eastern time.
The live call can be accessed by dialing (877) 558-3407 for domestic callers and (706) 679-1941 for international callers. The conference ID number is 22130601. A webcast of the live call can be accessed by visiting AVANIR's corporate website at www.avanir.com . To view the live webcast, please go to AVANIR's website prior to the start of the call to register, download, and install the necessary software.
An archived copy of the webcast will be available on AVANIR's website for 30 days, and a telephone replay will be available through November 6, 2010, by dialing (800) 642-1687 (domestic) or (706) 645-9291 (international) and entering the conference ID number 22130601.
NUEDEXTA™ is the first and only FDA-approved treatment for pseudobulbar affect (PBA). NUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations. NUEDEXTA acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which NUEDEXTA exerts therapeutic effects in patients with PBA is unknown.
NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurologi